Search
Search Results
-
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
BackgroundNeoadjuvant endocrine therapy (NET) in oestrogen receptor-positive (ER+) /HER2-negative (HER2-) breast cancer allows real-time evaluation...
-
Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
BackgroundPredictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-)...
-
Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy
BackgroundEndocrine therapy forms the backbone of adjuvant treatment for oestrogen-receptor-positive (ER+) breast cancer. However, it remains unclear...
-
Circulating Tumour Cell Isolation and Molecular Profiling; Potential Therapeutic Intervention
Comprehensive tumour characterisation is indispensable for patients to receive targeted therapy. The use of liquid biopsy, particularly circulating...
-
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling
BackgroundPIT1-positive pituitary adenoma (PIT1-PA) is one of the most important lineages of pituitary adenoma (PA), which causes systematic...
-
Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification
N6-methyladenosine (m6A), a posttranscriptional regulatory mechanism, is the most common epigenetic modification in mammalian mRNA. M6A modifications...
-
Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
To prevent the development of endocrine-resistant breast cancer, additional targeted therapies are increasingly being trialled in combination with...
-
Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence
BackgroundTumour infiltrating lymphocytes (TILs) are a prognostic parameter in triple-negative and human epidermal growth factor receptor 2...
-
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral...
-
Mutation-Attention (MuAt): deep representation learning of somatic mutations for tumour ty** and subty**
BackgroundCancer genome sequencing enables accurate classification of tumours and tumour subtypes. However, prediction performance is still limited...
-
RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity
BackgroundEndocrine-resistant breast cancers have elevated expression of XBP1, where it drives endocrine resistance by controlling the expression of...
-
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
ObjectiveTo investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role...
-
Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study
BackgroundCancer survivors have increased risk of endocrine complications, but there is a lack of information on the occurrence of specific...
-
Understanding tumour endothelial cell heterogeneity and function from single-cell omics
Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their success is limited owing to insufficient efficacy and...
-
Recent advances in cancer-on-a-chip tissue models to dissect the tumour microenvironment
Three-dimensional cancer-on-a-chip tissue models aim to replicate the key hallmarks of the tumour microenvironment and allow for the study of dynamic...
-
Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells
BackgroundAnti-oestrogenic therapy has been used for breast cancer patients with oestrogen susceptibility cancer cells. However, little has been...
-
Circulating tumour cell isolation, analysis and clinical application
BackgroundCirculating tumour cells (CTCs) are cancer cells that circulate in the bloodstream after being shed from solid tumours. They can lead to...
-
NK cells are never alone: crosstalk and communication in tumour microenvironments
Immune escape is a hallmark of cancer. The dynamic and heterogeneous tumour microenvironment (TME) causes insufficient infiltration and poor efficacy...
-
The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
BackgroundCurrently, the value of oral selective estrogen receptor degraders (SERDs) for hormone receptor-positive (HR+) and human epidermal growth...
-
Biology, vulnerabilities and clinical applications of circulating tumour cells
In recent years, exceptional technological advances have enabled the identification and interrogation of rare circulating tumour cells (CTCs) from...
